{rfName}
Ni

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Montero Gomez De Las Heras, ManuelAuthorNavarro MnCorresponding AuthorMittelbrunn MCorresponding Author

Share

May 24, 2021
Publications
>
Review
Hybrid Gold

Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing

Publicated to:BRITISH JOURNAL OF PHARMACOLOGY. 179 (9): 1839-1856 - 2022-05-01 179(9), DOI: 10.1111/bph.15477

Authors: Navarro, Maria N; Gomez de las Heras, Manuel M; Mittelbrunn, Maria

Affiliations

Consejo Superior de Investigaciones Científicas - Author
Hosp 12 Octubre i 12, Inst Invest Sanitaria, Madrid, Spain - Author
Hospital Universitario 12 de octubre - Author
Univ Autonoma Madrid UAM, Consejo Super Invest Cient CSIC, Ctr Biol Mol Severo Ochoa CBMSO, Dept Biol Mol, Madrid, Spain - Author
Univ Autonoma Madrid UAM, Interact Environm Program, Immune Syst Dev & Funct Unit, Ctr Biol Mol Severo Ochoa CBMSO,Consejo Super Inv, Madrid, Spain - Author
See more

Abstract

Metabolism is dynamically regulated to accompany immune cell function, and altered immunometabolism can result in impaired immune responses. Concomitantly, the pharmacological manipulation of metabolic processes offers an opportunity for therapeutic intervention in inflammatory disorders. The nicotinamide adenine dinucleotide (NAD ) is a critical metabolic intermediate that serves as enzyme cofactor in redox reactions, and is also used as a co-substrate by many enzymes such as sirtuins, adenosine diphosphate ribose transferases and synthases. Through these activities, NAD metabolism regulates a broad spectrum of cellular functions such as energy metabolism, DNA repair, regulation of the epigenetic landscape and inflammation. Thus, the manipulation of NAD availability using pharmacological compounds such as NAD precursors can have immune-modulatory properties in inflammation. Here, we discuss how the NAD metabolism contributes to the immune response and inflammatory conditions, with a special focus on multiple sclerosis, inflammatory bowel diseases and inflammageing. + + + + +

Keywords

ageingcd38experimental autoimmune encephalomyelitisinflammationnad+t cellsAgeingAutoimmunityCd38Energy metabolismExperimental autoimmune encephalomyelitisImmunityInflammationLymphocytesNadNad +Nad+SirtuinsT cells

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal BRITISH JOURNAL OF PHARMACOLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 24/278, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 8.12. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 6 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 10.81 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-04, the following number of citations:

  • WoS: 31
  • Scopus: 30
  • Europe PMC: 24

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 70.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 70 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 19.2.
  • The number of mentions on the social network X (formerly Twitter): 14 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (NAVARRO LOBATO, MARIA DE LAS NIEVES) and Last Author (MITTELBRUNN HERRERO, MARIA).

the authors responsible for correspondence tasks have been NAVARRO LOBATO, MARIA DE LAS NIEVES and MITTELBRUNN HERRERO, MARIA.